{"ModuleTitle": "Company Description", "CompanyName": "Rockwell Medical, Inc.", "Symbol": "RMTI", "Address": "411 HACKENSACK AVE., SUITE 501, HACKENSACK, New Jersey, 07601, United States of America", "Phone": "2489609009", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Rockwell Medical, Inc., together with its subsidiaries, (collectively, \"we,\"\r\n\"our,\" \"us,\" the \"Company\" or \"Rockwell\") is a biopharmaceutical company\r\ndedicated to transforming anemia and improving outcomes for patients across the\r\nglobe. We are initially targeting end-stage renal disease (\"ESRD\") and chronic\r\nkidney disease with innovative therapies and products for the treatment of iron\r\ndeficiency and hemodialysis (also referred to as \"dialysis\"). Our business\r\nstrategy is to bring our pharmaceutical products to market ourselves in the\r\nUnited States and to utilize partners to develop and commercialize such products\r\nin international markets.\r\n\r\nTriferic\u00ae (ferric pyrophosphate citrate) is the Company's proprietary iron\r\ntherapy that replaces iron and maintains hemoglobin in dialysis patients without\r\nincreasing iron stores. We believe Triferic is applicable to a wide variety of\r\ndisease states in which iron deficiency is an issue, and we are initially\r\ntargeting patients with ESRD.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f17%2f0001628280-20-003683.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Ajay Gupta", "title": "Chief Scientific Officer & Executive VP"}, {"name": "Angus W. Smith", "title": "Chief Financial Officer"}, {"name": "Marc Hoffman", "title": "Chief Medical Officer"}, {"name": "Michael DeYoung", "title": "Vice President-Operations"}, {"name": "Russell H. Ellison", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}